These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20687889)

  • 1. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients.
    Stankov MV; Behrens GM
    Curr Pharm Des; 2010 Oct; 16(30):3361-71. PubMed ID: 20687889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment.
    Giralt M; Díaz-Delfín J; Gallego-Escuredo JM; Villarroya J; Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3371-8. PubMed ID: 20687888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations.
    Caron-Debarle M; Boccara F; Lagathu C; Antoine B; Cervera P; Bastard JP; Vigouroux C; Capeau J
    Curr Pharm Des; 2010 Oct; 16(30):3352-60. PubMed ID: 20687886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
    Tanwani LK; Mokshagundam SL
    South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targets of metabolic toxicity of HIV antiretroviral drugs: the multiple roads to lipodystrophy and metabolic syndrome.
    Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3337-8. PubMed ID: 20687885
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxic metabolic syndrome associated with HAART.
    Haugaard SB
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):429-45. PubMed ID: 16863444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients.
    Srinivasa S; Grinspoon SK
    Eur J Endocrinol; 2014 May; 170(5):R185-202. PubMed ID: 24523497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
    Kotler DP
    J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic alterations in HIV-associated lipodystrophy syndrome].
    Valente AM; Reis AF; Machado DM; Succi RC; Chacra AR
    Arq Bras Endocrinol Metabol; 2005 Dec; 49(6):871-81. PubMed ID: 16544008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.
    Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP
    Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of the metabolic effects of HIV and HIV drugs.
    Brown TT; Glesby MJ
    Nat Rev Endocrinol; 2011 Sep; 8(1):11-21. PubMed ID: 21931374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.
    Flint OP; Noor MA; Hruz PW; Hylemon PB; Yarasheski K; Kotler DP; Parker RA; Bellamine A
    Toxicol Pathol; 2009 Jan; 37(1):65-77. PubMed ID: 19171928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome.
    Verkauskiene R; Dollfus C; Levine M; Faye A; Deghmoun S; Houang M; Chevenne D; Bresson JL; Blanche S; Lévy-Marchal C
    Pediatr Res; 2006 Aug; 60(2):225-30. PubMed ID: 16864709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed?
    Behrens GM; Stoll M; Schmidt RE
    Drug Saf; 2000 Jul; 23(1):57-76. PubMed ID: 10915032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
    Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
    Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV and its relationship to insulin resistance and lipid abnormalities.
    Non LR; Escota GV; Powderly WG
    Transl Res; 2017 May; 183():41-56. PubMed ID: 28068521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipose tissue biology and HIV-infection.
    Giralt M; Domingo P; Villarroya F
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):487-99. PubMed ID: 21663842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipodystrophy and metabolic disorders in anti-HIV therapy].
    Behrens GM; Stoll M; Schmidt RE
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():68-71. PubMed ID: 10863318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
    Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
    Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.